The Biotech Startups Podcast
Recently ranked · United States
Last recorded placements from this show’s chart history. These are not current rankings.
Not on the Germany charts we track today.
Not on the Brazil charts we track today.
Not on the New Zealand charts we track today.
Not on the Ireland charts we track today.
Not on the India charts we track today.
Not on the Japan charts we track today.
Not on the Philippines charts we track today.
Not on the South Africa charts we track today.
If you like The Biotech Startups Podcast, try…
Ranking history · United States
Latest daily rankings: Oct 31. New rankings will appear after the next update.
Recent history only — this show has no current ranking on the Science chart. These are recorded positions from the last 14 days, not current rankings.
Position on the Science combined chart over the last 14 days. Toggle platforms to compare their positions. Lower rank numbers are better.
View as table
| Date | Combined Rank | Apple Podcasts |
|---|---|---|
| Oct 31 | — | — |
| Oct 22 | #151 | #137 |
| Oct 21 | #163 | #150 |
| Oct 20 | #135 | #119 |
| Oct 19 | #149 | #133 |
| Oct 18 | #146 | #126 |
Latest episodes
-
🧬 He Chose Santa Barbara Over Icebergs | Steve Visco Rerelease (1/3)
October 26, 2026 · 35 minSteve Visco was an introverted kid with a microscope, pond water, and books on Louis Pasteur and Jonas Salk. School science lagged years behind what he was already doing at home. Literature almost pulled him into writing instead of the…
-
If It's Getting More Complex, You're Going the Wrong Way | Scott Chetham (4/4)
October 22, 2026 · 41 minScott Chetham explains why he left Google and Verily to tackle the unglamorous planning work that slows clinical development. He recounts sketching the company in Costa Rica, raising a pre-napkin-stage round with Polaris, finding an early…
-
The Clinical Trial Bottleneck Is Not Discovery | Scott Chetham (3/4)
October 19, 2026 · 31 minThe conversation then moves to the decisions that determine whether a trial succeeds: what to measure, whom to enroll, and when to measure it. Scott uses Amgen's osteoporosis strategy to show how a focused endpoint and staged market entry…
-
Knowledge Is Now a Commodity | Scott Chetham (2/4)
October 15, 2026 · 34 minThe conversation then turns to scaling teams through uncertainty. Scott shares how company growth creates organizational whiplash, why founders often underestimate the need for change management, and how leaders can stay close to what…
-
The Hard Part Starts After the Demo | Scott Chetham (1/4)
October 12, 2026 · 35 minScott Chetham traces the influences that shaped his path into life sciences, from growing up on Australia's Gold Coast and watching his parents build careers through work and education to studying the intersection of engineering and…
Show 7 more episodesShow fewer episodes
-
Letting Go Is a Leadership Skill | Leslie Loveless (4/4)
October 8, 2026 · 37 minAs Slone Partners grew beyond its original five-person team, Leslie Loveless had to confront one of the hardest parts of leadership: letting go. She talks about delegation, resisting the urge to rewrite everyone else's work, and learning…
-
The Employee Number Five Leap That Built a Relationship Business | Leslie Loveless (3/4)
October 5, 2026 · 33 minLeslie Loveless joined Slone Partners after a major personal transition, leaving a large healthcare company to become employee number five at a small recruiting firm. She hadn't worked in recruiting before, and at the time, she didn't…
-
Winning President's Club with Zero Sales Experience | Leslie Loveless (2/4)
October 1, 2026 · 27 minLeslie Loveless leaves the classroom for pharmaceutical sales in 1999, a coveted industry at the time. She describes the culture shock of moving from a school building into a territory-based role, where her days meant driving between…
-
How Teaching High School Prepares You to Run a Company | Leslie Loveless (1/4)
September 28, 2026 · 35 minLeslie Loveless starts at the beginning: growing up in a close-knit Indiana family, watching her father build a career as a pharmacist, and learning early that education mattered even if the eventual career path was left up to her.
-
The Catalyst Mindset Behind a Lean Biotech | Örn Almarsson (4/4)
September 24, 2026 · 25 minHe then turns to company building at Axelyf: in vivo cell reprogramming for solid tumors, modular lipid nanoparticles, AI-informed discovery, external partners, and a deliberately lean operating model. The conversation closes with the…
-
The Delivery Problem Behind Moderna's Breakthrough | Örn Almarsson (3/4)
September 21, 2026 · 29 minThe conversation covers layoffs, company transformation, patent cliffs, biotech's feast-and-famine cycles, modified mRNA, and the effort required to scale production from tiny academic batches to grams and kilograms.
-
Leaving Merck to Build a Biotech From Scratch | Örn Almarsson (2/4)
September 17, 2026 · 30 minAt Merck, a three-month visa detour exposed Örn to another laboratory and reinforced the value of adaptability. He then describes leaving a secure role for Transform Pharmaceuticals, building a small team and collaborative culture…

Australia
Brazil
Canada
Germany
India
Ireland
Japan
Mexico
New Zealand
Philippines
South Africa
United Kingdom